Hosted on MSN2d
Devils Must End First-Line Ondrej Palat Experiment; Full Analysis
When analyzing what prevents the New Jersey Devils from taking a healthy step forward from an inconsistent team with upside, ...
Healio1d
Baseline BMD T-score can help determine first-line therapy for women with osteoporosis
Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...
Targeted Oncology12d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
Wild center Joel Eriksson Ek out at least ‘a few weeks’ with lower-body injury
Minnesota Wild first-line center Joel Eriksson Ek has been placed on injured reserve on with a lower-body injury. The team ...
Monthly Prescribing Reference5d
Nivolumab + Ipilimumab Under Review for First-Line Treatment of MSI-H/dMMR mCRC
A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...
Targeted Oncology5d
FDA Accepts sBLA for Nivolumab/Ipilimumab Combo in dMMR/MSI-H CRC
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
Cancer Therapy Advisor12d
Cemiplimab Plus Chemotherapy May Be New First-Line Option for Penile Cancer
First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients with advanced penile carcinoma.
Cape Cod Times5d
Allen Gunn names his last boys and girls hockey Lines of the Week of the 2024-25 season
As the page flips to playoff hockey, several for Cape and Islands players turned in one last regular season impression to ...
Business Wire12d
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL ...
in combination with BTK inhibitor orelabrutinib as a first-line therapy for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in China. ICP-248 ...